Xiuning Le MD PhD

302 posts

Xiuning Le MD PhD banner
Xiuning Le MD PhD

Xiuning Le MD PhD

@LeXiuning

Associate Professor Thoracic Head and Neck Medical Oncology MD Anderson Cancer Center

Houston, TX Katılım Mart 2020
374 Takip Edilen2.1K Takipçiler
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Strongly support my @UTMDAnderson colleague Dr. Hussein Tawbi @HTawbi_MD for #SITC Director election ❤️💐 👉Hussein is an internally renowned #physicianscientist immune-oncology leader who has helped redefine what immunotherapy can achieve in some of the most challenging clinical settings. 👉His leadership of the CheckMate 204 study established the role of nivolumab + ipilimumab in melanoma brain metastases, a historically underserved population, 👉He led RELATIVITY-047 which enabled the approval of nivolumab + relatlimab, introducing LAG-3 as a new checkpoint target. His voice and compassion, grounded in patient care and scientific rigor, would be an outstanding addition to the #SITC Board as we navigate the next era of immunotherapy innovation. 🚀
Xiuning Le MD PhD tweet media
Society for Immunotherapy of Cancer@sitcancer

The #SITC election starts on Friday! The three At-Large Directors who receive the plurality of votes will begin three-year terms in 2027. Read the biographies and platform statements of this year’s candidates at #ald" target="_blank" rel="nofollow noopener">sitcancer.org/get-involved/2…

English
0
2
6
703
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Strongly support Dr. Zhen Su @MyOncology , my friend, colleague, and mentor for SITC Director election. 💪❤️ 👉When he served as the global oncology leader at #MerckKGaA/#EMDSerono, he translated complex immune biology to approvals, then becaome impactful therapies for patients. He has multiple global approvals across agents such as #avelumab, #tepotinib, #erbitux and others. 👉Now as the CEO of #Marengo, he is a true architect with vision, taking first-in-class T-cell agonist programs from platform stage into human studies and secured strong partnerships. 👉Zhen has been a long-standing contributor to the #immuno-oncology community, including leadership roles within #SITC. His vision of bringing early discovery to global commercialization will continue shaping the development of next generation immunotherapies. 🚀
Xiuning Le MD PhD tweet media
Society for Immunotherapy of Cancer@sitcancer

The #SITC election starts on Friday! The three At-Large Directors who receive the plurality of votes will begin three-year terms in 2027. Read the biographies and platform statements of this year’s candidates at #ald" target="_blank" rel="nofollow noopener">sitcancer.org/get-involved/2…

English
0
1
11
1.1K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Appreciate @StephenVLiu and @CharuAggarwalMD organizing a fantastic US Focus Meeting Lung Cancer. I discussed 1L EGFR-mut NSCLC landscape evolution with friends and colleagues @riess_md @JuliaRotow @JustinGainor @ShirishGadgeel @BalazsHalmosMD. Nashville is a charming city with such fun characters.
Xiuning Le MD PhD tweet mediaXiuning Le MD PhD tweet mediaXiuning Le MD PhD tweet mediaXiuning Le MD PhD tweet media
Stephen V Liu, MD@StephenVLiu

Inaugural US Focus Meeting on Lung Cancer from @_MDEducation starts in Nashville with EGFR session. Great overviews by Drs. @LeXiuning Liza Villaruz @ZPiotrowskaMDand panel chaired by @CharuAggarwalMD. Great areas for discussion including LCT, bispecifics, and ADCs.

English
0
1
12
1.7K
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
For those who plan way in advance, September 2027 will be a tough month for lung cancer meetings! #ESMO27 in Barcelona, Spain will be September 17-21. #WCLC27 in Denver, USA will be September 11-14. Will be challenging to attend both in person; grateful for virtual options!
Stephen V Liu, MD tweet mediaStephen V Liu, MD tweet media
English
3
2
55
6.6K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
😊 🩷 Nice to see friends and colleagues in the #lungcancer community from different continents at #ELCC26. @caliraf @Alfdoc2 @HHorinouchi @MartinReck2 @Tony_Calles @DoctorJSpicer @fred_hirsch @bensolomon1 @NReguart @BalazsHalmosMD @BrendonStilesMD @mollylisc @karenkellymd @ThomasW35874311 @NadalErnest @DrSanjayPopat 😊 🩷 Safe travels ✈️ 💐💐💐Grateful for the wonderful organization between @IASLC and @esmo for an impactful and fun #ELCC26.
Xiuning Le MD PhD tweet media
English
1
7
47
2.6K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
We discussed innovations in ADCs to overcome topo-payload ADC resistance. 🔥Novel payloads include dual-cytotoxic, radioligands, immune stimulators or engagers, oligonucleotides (siRNA), degraders, and small molecule inhibitors. 🤣 Yes, "Any-Drug-Conjugates (ADC)" ❤️💡
Mario Balsa@MarioBalsaMD

💥 Beyond traditional ADCs at #ELCC26! @LeXiuning ▪️Masked ADCs → tumor-activated targeting ▪️Nanobodies & peptides: better penetration, new epitopes ▪️Bicycle toxin conjugates: ultra-small, fast delivery 🎯 Innovation across 3 axes: target, linker, payload From ADCs to “anything-drug conjugates” @OncoAlert @myESMO @OncoReporte @_SEOM @gecp_org @Lung_Cancers

English
3
10
40
3.7K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Honored to be delivering two educational lectures at 🔜 #ELCC26 @myESMO🇩🇰 in Copenhagen. 📍 March 26. 👉Beyond traditional ADCs: Advances in targeting, conjugation, payload design, and emerging modalities 📍 March 28 👉Mechanisms of resistance: Lessons from EGFR-mutant and ALK-rearranged NSCLC 💐Grateful to the conference chairs @DrSanjayPopat @APassaroMD for your excellent work on organizing #ELCC26. 💗Looking forward to great discussions and connecting with global colleagues @HHorinouchi @ThomasW35874311 @Alfdoc2 @caliraf @tnewsomdavis @YYElamin @lungoncdoc
Xiuning Le MD PhD tweet media
English
2
12
55
2.8K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Please (re)watch the powerful Special Speech delivered by Dr. Ross Camidge @DRCamidge at #TTLC26 @IASLC An internationally renowned thoracic oncologist, Dr. Camidge shared something profoundly personal: his own diagnosis and treatment journey with stage IV #EGFR-mutant #NSCLC. His reflections were thoughtful and deeply human. It is a reminder that before we are physicians or patients, we are human beings: vulnerable yet resilient. Please: ❤️ Act with urgency. ❤️ Treat with respect and gentleness. ❤️ Move forward with courage and hope. @ShirishGadgeel @lungoncdoc @KarenReckampMD @TejasPatilMD
IASLC@IASLC

At #TTLC26, @DRCamidge shared powerful insights shaped by both clinical expertise and personal experience living with #lungcancer. His presentation reminds us why continued innovation in #lungcancer research is essential to improving patient outcomes every day. bit.ly/46YrbUc

English
0
9
33
2.9K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
❤️ ❤️ So happy and proud to wrap up a successful #TTLC26 @IASLC 💐🎊 👉 This year, we set new records: 🥇 🔥 the highest attendance, 🥇 🔥 the greatest number of submitted abstracts, and 🥇 🔥 unprecedented sponsorship support. 👉 This year, we hosted two extraordinary keynote speakers: my mentor Dr. John Heymach @MDAndersonNews and his mentor Dr. Bruce E. Johnson. Seeing multiple generations of thoracic oncology leadership on one stage was a powerful reminder that progress in our field is built on mentorship, collaboration, and legacy. Let it continue. ❤️ ❤️ Special appreciation to my dear co-chairs @ShirishGadgeel @KarenReckampMD and Dr. Paul Bunn, and outstanding @IASLC staff, especially Kelly Heemsbergen, for being consistently knowledgeable, responsive, and supportive behind the scenes. 👉 See you all again at hashtag #TTLC27
Xiuning Le MD PhD tweet media
English
1
8
49
2K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Join us for the 26th Annual Targeted Therapies of Lung Cancer Meeting in Huntington Beach 🌴 🏖️ , with nation's leading experts in thoracic oncology. lnkd.in/grFDmjVA With my co-chairs, Drs @ShirishGadgeel @KarenReckampMD, Paul Bunn, we especially encourage junior faculty and oncology fellows to participate. The meeting offers a unique opportunity for academic mentorship, scientific exchange, and meaningful connections with industry partners. @MDAndersonNews @oncodaily
IASLC@IASLC

The countdown to #TTLC26 is on! 🧬 Join leading minds to explore what’s next in clinical research and targeted therapies. Don’t miss the conversations shaping the future: bit.ly/3KP8GtL

English
1
8
37
3.1K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
For #EGFR #PACC mutation #lungcancer, novel TKIs are in active investigation, the next key questions are: 👉1. Single vs. compound PACC mutations 👉2. co-mutation's impact to treatment 👉3. tumor immune microenvironment difference 👉4. strategies for overcoming resistance. Thank you ❤️@gotoPER #WinterLung26 @EdgardoSantosMD @MarkSocinski for providing this dynamics discussion platform
Edgardo Santos, MD, FACP, FASCO@EddieSantosMD

Outstanding presentation by Prof Xiuning Le from MDACC on EGFR PACC mutation; the importance of identifying and reporting them and the new clinical trials in this space. Here at the 23th WLC. @LeXiuning @MarkSocinski @OncologyInst @FLASCO_ORG @gotoPER #WLC26 @edgardo_ny

English
3
9
44
3.8K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
📖 New online from our group at @MDAndersonNews Mechanisms of Resistance to Trastuzumab-DXd in #LungCancer 🔬✨ Key findings: 👉 Payload resistance driven by #SLFN11 loss and copy-number gains in the efflux pump ABCC1/MRP1 👉 Secondary #HER2 extracellular domain mutations at the antibody binding site (e.g., D582, F595) 👉 Tumors with acquired payload resistance or domain IV mutations retain HER2 signaling and remain sensitive to TKIs, including #zongertinib and #sevabertinib 💡 🎊 🔥 This is the first comprehensive preclinical and clinical investigation of #ADC #MoR in lung cancer, with direct therapeutic implications. jto.org/article/S1556-…
Xiuning Le MD PhD tweet media
English
2
47
164
14.8K
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
Congratulations to 🌟🎊Dr. Ximeng Liu for been selected for support from the Lung Cancer Research Foundation (@lcrf_org ) for her project: “Deciphering response and resistance mechanisms to firmonertinib in #NSCLC patients with #EGFR #PACC mutations.” 🔬💡 Our journey has been remarkable: 👉 2021: Defined #EGFR #PACC mutations as a distinct structure–function subgroup in lung cancer. 👉 2023–2024: Partnered with ArriVent Biopharma on the first prospective trial dedicated to EGFR PACC patients — 68% response rate and 16.0 months PFS with #firmonertinib. 👉 2025: Launched the first global randomized phase III trial in EGFR PACC–mutant NSCLC (ALPACCA/FURMO-006; NCT07185997) 🌍🧪 👉 2026–2027: With @lcrf_org support, Dr. Liu will lead efforts to decipher resistance mechanisms and shape next-generation therapeutic strategies. 🚀 More exciting developments are on the horizon. lungcancerresearchfoundation.org/research/our-i…
Xiuning Le MD PhD tweet media
English
0
1
28
2.5K

Keşfet

@UTMDAnderson @HTawbi_MD @MyOncology @StephenVLiu @CharuAggarwalMD @riess_md @JuliaRotow @JustinGainor